slides · global inventory
Expose Contradiction
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 14,162
Current window 3,331-3,360
Pages 473
Rows per page 30
Slide function
3,331-3,360 of 14,162
03
This slide serves as a critical analysis of clinical trial integrity, specifically focusing on the SONAR trial and subsequent reporting practices.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The Monster1 hit
06
The slide uses data from the RADAR trial to challenge the validity of UACR as a reliable surrogate endpoint for kidney function.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
07
The text argues that the rapid reversal of UACR effects upon drug cessation indicates a transient hemodynamic impact rather than structural renal improvement.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
09
The slide uses Kaplan-Meier survival curves to illustrate the convergence of outcomes between placebo and Atrasentan groups.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
11
The slide functions as a critique of clinical trial data integrity, specifically focusing on the inclusion of serum creatinine doubling and the use of inulin as a gold standard.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
12
The slide uses bar charts to show baseline vs treatment effects on GFR, ERBF, EFF, and ERVR, suggesting these metrics are influenced by blood dilution.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
13
The slide uses a table to highlight discrepancies in mortality reporting between the 'Enrichment' group and the 'Double-Blind' groups.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
15
The text explicitly alleges data tampering regarding Acute Kidney Injury (AKI) reporting in the SONAR study.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
17
The slide uses a table to highlight inconsistent reporting of Acute Kidney Injury (AKI) across different study groups and provides a narrative critique of cardiac failure reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
20
The text argues that the omission of hematocrit data in the SONAR trial masks a hemodynamic effect that would undermine claims of renal improvement.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
21
The slide uses a callout box for trial results and follows with a critical analysis of anemia as a side effect.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
25
The slide critiques the visual representation of clinical trial data, specifically the 'time-distorting' nature of the x-axis in the provided graph.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
26
The slide highlights inconsistencies between SONAR study reports and FDA filings, suggesting data manipulation to favor the drug's safety profile.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
27
The slide uses a table of clinical trial results to illustrate a methodological critique of composite endpoints.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
28
The text focuses on statistical manipulation in clinical trial endpoints and discrepancies in patient count reporting between AFFINITY and ALIGN studies.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
29
The slide uses a 'villain critique' approach to undermine the credibility of the company's clinical trial reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
30
The slide uses a combination of text-based argument and visual data (charts) to expose potential manipulation of clinical trial reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
23
The slide uses footnotes to cite sources for claims about rent24's occupancy and the Fürst property valuation.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Struggle1 hit
24
Includes a photograph of a building directory as evidence of tenant occupancy; references footnotes 44 and 45.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Struggle1 hit
25
The slide uses a table to provide context for a forensic argument about asset inflation. Footnotes 46-48 provide specific source citations for the claims.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
26
The slide uses a forensic accounting approach to challenge the legitimacy of fair value gains reported by Vivion.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
28
Includes two data tables detailing pre-rent NOI and rent inflation estimates for Ribbon and Hallmark portfolios.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
29
The slide highlights potential misappropriation and conflicts of interest in property transactions.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
30
The slide functions as a forensic investigation into a specific transaction chain, highlighting the use of nominees and rapid asset flipping.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
31
Includes footnotes 63-66. The slide highlights a discrepancy between reported transaction values and subsequent fair value gains.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
32
The slide uses a Wayback Machine screenshot as primary evidence to link property ownership across entities.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
34
The slide highlights a discrepancy between reported valuation stability and the reliance on internal assessments.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
37
The slide uses a narrative structure to expose financial complexity and potential fraud, referencing specific entities and dates.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
02
The slide sets up a 'before/after' or 'reality vs. representation' critique typical of short-seller research notes.Vivion Investments · Carson Block
Research note Short seller Beat · Expose Contradiction1 hit
04
The slide uses a news headline as a hook to introduce a valuation discrepancy argument.Vivion Investments · Carson Block
Research note Short seller Beat · Thesis Headline1 hit